Neervannan Seshadri 4

4 · Tarsus Pharmaceuticals, Inc. · Filed Mar 17, 2026

AI-generated summary of this filing

Updated Mar 17, 2026

Tarsus (TARS) COO Neervannan Seshadri Receives RSU Settlement

What Happened

Neervannan Seshadri, Chief Operating Officer of Tarsus Pharmaceuticals (TARS), had 26,287 restricted stock units (RSUs settle/convert) vest on March 15, 2026. The company issued 26,287 shares pursuant to settlement of vested RSUs (reported as an acquisition), and an equal total of 26,287 shares were recorded as dispositions at $0.00 to satisfy tax withholding. No cash proceeds were reported and the transaction appears to be a routine vest-and-withhold event rather than an open-market buy or sell.

Key Details

Transaction date: March 15, 2026; Form 4 filed March 17, 2026 (timely filing).
Gross shares issued: 26,287 (RSU settlement). Shares withheld/disposed for taxes: 5,097 + 8,148 + 8,020 + 5,022 = 26,287.
Reported prices: issuance N/A for RSU settlement; withholding/disposals recorded at $0.00 (no cash sale proceeds).
Footnotes: F1 confirms shares issued upon settlement of vested RSUs. F3–F7 describe the RSU grants and vesting schedules (grants from 2022–2025 with 25% vesting each March 15 of the applicable years). F2 discloses a household holding (the Reporting Person’s daughter) and disclaims beneficial ownership of those shares.
Shares owned after the transaction are not specified in the provided excerpt.

Context

This was a scheduled RSU vesting and tax-withholding event (not a market sale). The Form shows conversion/settlement of RSUs (derivative code M) and immediate withholding of an equivalent number of shares for taxes—common for RSU settlements and not necessarily reflective of insider sentiment.

Form 4

Period: 2026-03-15

Chief Operating Officer

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-03-15+26,287→ 97,104 total
Exercise/Conversion
Restricted Stock Units
[F3][F4]
2026-03-15−5,097→ 0 total
→ Common Stock (5,097 underlying)
Exercise/Conversion
Restricted Stock Units
[F3][F5]
2026-03-15−8,148→ 8,148 total
→ Common Stock (8,148 underlying)
Exercise/Conversion
Restricted Stock Units
[F3][F6]
2026-03-15−8,020→ 16,040 total
→ Common Stock (8,020 underlying)
Exercise/Conversion
Restricted Stock Units
[F3][F7]
2026-03-15−5,022→ 15,067 total
→ Common Stock (5,022 underlying)

Holdings

Footnotes (7)

[F1]The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").
[F2]This holding balance is related to the Reporting Person's daughter who shares the Reporting Person's household. The Reporting Person disclaims beneficial ownership of the securities held by his daughter, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purposes.
[F3]Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock.
[F4]RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs vested on March 15th of each of 2023, 2024, 2025 and 2026.
[F5]RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.
[F6]RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.
[F7]RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service.

Signature

/s/ Jeffrey Farrow, Attorney-in-Fact|2026-03-17

1 file